Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users

PHASE4CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

January 20, 2017

Primary Completion Date

June 5, 2019

Study Completion Date

June 5, 2019

Conditions
BleedingImplantsBreakthrough Bleeding
Interventions
DRUG

Tamoxifen

Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study

DRUG

Placebo

Placebo orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study

DRUG

Tamoxifen (open label)

Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the second 90 days of the study

Trial Locations (1)

97239

OHSU, Portland

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Oregon Health and Science University

OTHER

NCT02903121 - Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users | Biotech Hunter | Biotech Hunter